November 14-16, 2017
Boston, MA

LinkedIn Icon

Workshop A
Tuesday, November 14 2017

09.00 - 12.00
Systematic Screening for T-cell and Antibody Targets in Cancer

Workshop Leader: Johanna Olweus, Professor, Director, K.G. Jebsen Center for Experimental Immunotherapy, University of Oslo

Treatment with CAR T cells was recently approved by the FDA on basis of clinical efficacy in B-cell malignancies. CARs are immune receptors generated from antibodies that recognize cell surface proteins, whereas T-cell receptors can recognize peptides from any cellular protein. A limitation for development of immune-gene therapy in the majority of cancer types is the scarcity of molecules that can be targeted in a safe and efficacious manner by CARs or T-cell receptors. Thus, there is a need for high-throughput strategies to identify therapeutic targets and their cognate T-cell receptors and antibodies.

What will be discussed:

  • Identification of immunogenic neoantigens using healthy donor T cells: Blood samples from cancer patients are scarce, and T cells from cancer patients react to only 1-2% of neoantigens. Blood from healthy donors represent an alternative and unlimited source of neoantigen-reactive T cells and T-cell receptors. During the workshop Olweus will discuss the use of healthy donor T cells as a source for neo-antigen-specific T-cell receptors and as tools to screen for immunogenic neoantigens.
  • Proteome-wide screening for tumor-reactive antibodies. Serum antibodies in cancer patients might be important biomarkers of anti-cancer immune reactivity, and identify candidate targets of immunotherapy. Additionally, they might serve as indicators of T-cell reactivity. Olweus will discuss how protein arrays can be used to screen patient serum for antibodies to tumor-associated proteins.

Johanna Olweus, Professor, Director, K.G. Jebsen Center for Experimental Immunotherapy, University of Oslo

Johanna Olweus

Workshop B
Tuesday, November 14 2017

13.00 - 16.00
An “Off the Shelf” Vaccine Based on Shared Tumor Neoantigens for Prevention and Treatment of MicroSatellite Instable Cancers

Workshop Leader: Elisa Scarselli, CSO , Nouscom



”Targeted” immunotherapeutic approaches have become increasingly prominent in the last several years. Learn from the CSO of Nouscom as she shares their strategy
from recent therapeutic achievements in the fields of cancer immunotherapy. Hear their plans to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells and details of one of their shared antigen programs. Leave this workshop with the practical guidance you need to ensure
you are ready to take your research to the next level.

What will be discussed?

  • MicroSatellite Instable cancers harbor shared mutations that can generate frame shift peptides offering the opportunity for an “off the shelf” vaccine based on a large number of frame shift peptides neoantigens
  • The selected collection of frame shift peptides for the vaccine has a high potential coverage for MSI cancers
  • Vaccination with Adenovectors encoding for the shared neoantigens can induce a powerful T cell response in mice

Elisa Scarselli, CSO , Nouscom

elisa